UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Current perspectives for SARS-CoV-2 vaccination efficacy improvement in patients with active treatment against cancer

European journal of cancer (1990), 2021-09, Vol.154, p.66-72

2021

Volltextzugriff (PDF)

Comparative analysis of two HIV-1 multiepitope polypeptides for stimulation of immune responses in BALB/c mice

Molecular immunology, 2020-03, Vol.119, p.106-122

2020

Volltextzugriff (PDF)

Listeria-Vectored Vaccine Expressing the Mycobacterium tuberculosis 30-Kilodalton Major Secretory Protein via the Constitutively Active prfA Regulon Boosts Mycobacterium bovis BCG Efficacy against Tuberculosis

Infection and immunity, 2017-09, Vol.85 (9)

2017

Volltextzugriff (PDF)

Systematic Review of the SARS-CoV-2 Viral Vector Vaccine AstraZeneca (Azd1222)

Bioscientific review, 2022-06, Vol.4 (2), p.1-20

2022

Volltextzugriff (PDF)

Exploring heterologous prime-boost vaccination approaches to enhance influenza control in pigs

Veterinary research (Paris), 2020-07, Vol.51 (1), p.89-89, Article 89

2020

Volltextzugriff (PDF)

Antibody and T Cell Responses against SARS-CoV-2 Elicited by the Third Dose of BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) Vaccines Using a Homologous or Heterologous Booster Vaccination Strategy

Vaccines (Basel), 2022-03, Vol.10 (4), p.539

2022

Volltextzugriff (PDF)

Homologous versus Heterologous prime-boost COVID-19 Vaccination in autologous hematopoietic stem cell transplantation recipients: a blinded randomized controlled trial

Frontiers in immunology, 2023-08, Vol.14, p.1237916-1237916

2023

Volltextzugriff (PDF)

Heterologous prime boost COVID 19 vaccination

Infectious diseases now (Online), 2022-11, Vol.52 (8S), p.S7-S8

2022

Volltextzugriff (PDF)

Transient T Cell Expansion, Activation, and Proliferation in Therapeutically Vaccinated Simian Immunodeficiency Virus-Positive Macaques Treated with N-803

Journal of virology, 2022-12, Vol.96 (23), p.e0142422

2022

Volltextzugriff (PDF)

Efficient stabilization of therapeutic hepatitis B vaccine components by amino-acid formulation maintains its potential to break immune tolerance

JHEP reports, 2023-02, Vol.5 (2), p.100603-100603, Article 100603

2023

Volltextzugriff (PDF)

Heterologous Prime-Boost Vaccination with Inactivated Influenza Viruses Induces More Effective Cross-Protection than Homologous Repeat Vaccination

Vaccines (Basel), 2023-07, Vol.11 (7), p.1209

2023

Volltextzugriff (PDF)

An optimized peptide vaccine strategy capable of inducing multivalent CD8+ T cell responses with potent antitumor effects

Oncoimmunology, 2015-11, Vol.4 (11), p.e1043504-e1043504

2015

Volltextzugriff (PDF)

CpG enhances the immunogenicity of heterologous DNA-prime/protein-boost vaccination with the heavy chain myosin of Brugia malayi in BALB/c mice

Parasitology research (1987), 2019-06, Vol.118 (6), p.1943-1952

2019

Volltextzugriff (PDF)

Higher SARS-CoV-2 Spike Binding Antibody Levels and Neutralization Capacity 6 Months after Heterologous Vaccination with AZD1222 and BNT162b2

Vaccines (Basel), 2022-02, Vol.10 (2), p.322

2022

Volltextzugriff (PDF)

Transcriptional response to a prime/boost vaccination of chickens with three vaccine variants based on HA DNA and Pichia-produced HA protein

Developmental and comparative immunology, 2018-11, Vol.88, p.8-18

2018

Volltextzugriff (PDF)

In vivo electroporation in DNA-VLP prime-boost preferentially enhances HIV-1 envelope-specific IgG2a, neutralizing antibody and CD8 T cell responses

Vaccine, 2017-04, Vol.35 (16), p.2042-2051

2017

Volltextzugriff (PDF)

A Randomized Clinical Trial of a Fractional Low Dose of BNT162b2 Booster in Adults Following AZD1222

Vaccines (Basel), 2022-06, Vol.10 (6), p.914

2022

Volltextzugriff (PDF)

Development of cattle TB vaccines in the UK

Veterinary Immunology and Immunopathology, 2006-07, Vol.112 (1), p.38-48

2006

Volltextzugriff (PDF)

Immunomodulatory Gene Therapy

Viral Therapy of Cancer, 2008, p.277-294

2008

Volltextzugriff (PDF)

Homologous or heterologous administration of mRNA or adenovirus-vectored vaccines show comparable immunogenicity and effectiveness against the SARS-CoV-2 omicron variant

Expert review of vaccines, 2024-12, Vol.23 (1), p.432-444

2024

Volltextzugriff (PDF)

Mouse study of combined DNA/protein COVID-19 vaccine to boost high levels of antibody and cell mediated immune responses

Emerging microbes & infections, 2023-12, Vol.12 (1), p.2152388-2152388

2023

Volltextzugriff (PDF)

Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March-June 2021, England

Euro surveillance : bulletin européen sur les maladies transmissibles, 2021-07, Vol.26 (28), p.1

2021

Volltextzugriff (PDF)

Robust and protective immune responses induced by heterologous prime‐boost vaccination with DNA‐protein dimeric RBD vaccines for COVID‐19

Journal of medical virology, 2023-07, Vol.95 (7), p.e28948-n/a

2023

Volltextzugriff (PDF)

Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates

Emerging microbes & infections, 2021, Vol.10 (1), p.629-637

2021

Volltextzugriff (PDF)

Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals

Vaccine, 2023-03, Vol.41 (12), p.1925-1933

2023

Volltextzugriff (PDF)

1 – 25 von 73

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(69)
Mit Volltextzugriff
(70)

Publikationsform

Artikel
(71)
Buchkapitel
(2)

Sprache

Englisch
(73)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Current perspectives for SARS-CoV-2 vaccination efficacy improvement in patients with active treatment against cancer

Comparative analysis of two HIV-1 multiepitope polypeptides for stimulation of immune responses in BALB/c mice

Listeria-Vectored Vaccine Expressing the Mycobacterium tuberculosis 30-Kilodalton Major Secretory Protein via the Constitutively Active prfA Regulon Boosts Mycobacterium bovis BCG Efficacy against Tuberculosis

Systematic Review of the SARS-CoV-2 Viral Vector Vaccine AstraZeneca (Azd1222)

Exploring heterologous prime-boost vaccination approaches to enhance influenza control in pigs

Antibody and T Cell Responses against SARS-CoV-2 Elicited by the Third Dose of BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) Vaccines Using a Homologous or Heterologous Booster Vaccination Strategy

Homologous versus Heterologous prime-boost COVID-19 Vaccination in autologous hematopoietic stem cell transplantation recipients: a blinded randomized controlled trial

Heterologous prime boost COVID 19 vaccination

Transient T Cell Expansion, Activation, and Proliferation in Therapeutically Vaccinated Simian Immunodeficiency Virus-Positive Macaques Treated with N-803

Efficient stabilization of therapeutic hepatitis B vaccine components by amino-acid formulation maintains its potential to break immune tolerance

Heterologous Prime-Boost Vaccination with Inactivated Influenza Viruses Induces More Effective Cross-Protection than Homologous Repeat Vaccination

An optimized peptide vaccine strategy capable of inducing multivalent CD8+ T cell responses with potent antitumor effects

CpG enhances the immunogenicity of heterologous DNA-prime/protein-boost vaccination with the heavy chain myosin of Brugia malayi in BALB/c mice

Higher SARS-CoV-2 Spike Binding Antibody Levels and Neutralization Capacity 6 Months after Heterologous Vaccination with AZD1222 and BNT162b2

Transcriptional response to a prime/boost vaccination of chickens with three vaccine variants based on HA DNA and Pichia-produced HA protein

In vivo electroporation in DNA-VLP prime-boost preferentially enhances HIV-1 envelope-specific IgG2a, neutralizing antibody and CD8 T cell responses

A Randomized Clinical Trial of a Fractional Low Dose of BNT162b2 Booster in Adults Following AZD1222

Development of cattle TB vaccines in the UK

Immunomodulatory Gene Therapy

Homologous or heterologous administration of mRNA or adenovirus-vectored vaccines show comparable immunogenicity and effectiveness against the SARS-CoV-2 omicron variant

Mouse study of combined DNA/protein COVID-19 vaccine to boost high levels of antibody and cell mediated immune responses

Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March-June 2021, England

Robust and protective immune responses induced by heterologous prime‐boost vaccination with DNA‐protein dimeric RBD vaccines for COVID‐19

Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates

Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals

Suchergebnisse filtern